U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07499362) titled 'Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)' on March 23.
Brief Summary: The primary purpose of this study is to assess the tolerability, pharmacokinetics, and efficacy of pimicotinib in Japanese participants with TGCT
Study Start Date: April 27
Study Type: INTERVENTIONAL
Condition:
Tenosynovial Giant Cell Tumor
Intervention:
DRUG: Pimicotinib
In the Safety Run-in Cohort, participants will receive 50 milligrams (mg) of pimicotinib once daily (QD), orally in 28-day cycles until disease progression (DP), death, discontinuation, or any other reason. The Safety Monitoring ...